Sanofi Stock Declined 0.9% Last Week After FDA Issued CRL for Tolebrutinib

Key Stats for Sanofi Stock

• Past-Week Performance: -0.92%
• 52-Week Range: €76 to €111
• Valuation Model Target Price: €100
• Implied Upside: 27.5% 1.9 over years

Sanofi moved amid mixed regulatory signals, but how sensitive is its valuation to growth and margin assumptions? Stress-test the model on TIKR for free →

What Happened?

Sanofi (SAN) fell 0.9% over the past week, with the move broadly tied to recent regulatory and corporate developments.

The move followed mixed news flow, including an FDA complete response letter for tolebrutinib alongside earlier China approvals and the announced Dynavax acquisition.

This mattered because regulatory setbacks weighed on sentiment, reflecting valuation sensitivity and execution risk rather than changes to near-term operating performance.

Sanofi saw no changes to guidance, demand trends, or its long-term outlook, and recent actions did not alter the company’s stated financial framework.

The move reflects a recalibration of expectations rather than a deterioration in the underlying business following mixed regulatory signals.

Pipeline approvals and setbacks drove expectations, not guidance changes. See how those assumptions translate into Sanofi’s valuation using TIKR for free →

Is Sanofi Stock Fairly Valued Right Now?

Under the valuation model shown, the stock is modeled using:

• Revenue Growth: 6.3%
• Operating Margins: 29.4%
• Exit P/E Multiple: 9.5x

Under a guided valuation model realized through December 2027, Sanofi stock’s valuation outcome depends on modeled revenue growth, margin stability, and exit multiple assumptions holding.

The model assumes 6.3% revenue CAGR, 28.4% operating margins, and a 9.5x exit P/E multiple over the forecast period.

Based on these inputs, the model estimates a €99.93 target price, implying 27.5% total returns and 13.3% annualized returns.

Achieving this outcome depends on consistent pipeline execution, stable pricing, margin discipline, and continued scale across core pharmaceuticals and vaccines.

Overall, the valuation reflects execution risk rather than optimism, and Sanofi’s stock may remain sensitive to regulatory and operational developments.

After recent biotech and vaccine-related developments, explore whether Sanofi’s implied returns still depend on execution by running a valuation on TIKR for free →

Value Any Stock in Under 60 Seconds (It’s Free)

With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.

All it takes is three simple inputs:

1. Revenue Growth
2. Operating Margins
3. Exit P/E Multiple

From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.

If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.

Sanofi’s stock reacted to expectation recalibration rather than fundamentals. Test how regulatory outcomes affect long-term valuation using TIKR’s tools for free →